208. TRIHEXYPHENIDYL REDUCES FLASHBACKS IN PATIENTS WITH POSTTRAUMATIC STRESS DISORDER (PTSD)

Abstract Background Post-Traumatic Stress Disorder (PTSD) is a complex mental health condition triggered by experiencing or witnessing traumatic events. Despite extensive research, the precise mechanisms underlying PTSD remain unclear. Recent data from patients have shown that central cholinergic agents targeting the basal forebrain nucleus AcH4 and the amygdala, which are involved in memory-related circuits, have demonstrated dramatic effects in alleviating PTSD symptoms. Aims & Objectives This study aims to develop a new therapy for reducing flashbacks in the posttraumatic stress disorder (PTSD). Method Previous studies have proved the potentiality of anticholinergic in reducing flashbacks in PTSD. This report describes the effects of the central anticholinergic drug trihexyphenidyl, which penetrates the blood–brain barrier (BBB) among 7 patients suffering from PTSD flashbacks. Results Drug effects were assessed using psychological tests, including a self-evaluation score, the IES-R (Impact of Events Scale-Revised), and CAPS (Clinician-administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders-IV [DSMIV]).The mean of the self-evaluation score improved from 100 to 17.14 after the treatment, and the mean IES-R score improved to 25.57 from 70.42. The CAPS mean frequency (F) and intensity (I) of B-1(unwanted memories) improved from 3.42 to0.71and 3.42 to 0.57, respectively, after treatment. The mean F and I of B-2 (unpleasant dreams) improved from 1.85 to 0.42and 2.00 to 0.28, respectively. The mean of F and I of B-3 (flashbacks, etc.) improved from 3.71 to 0.85 and 3.28 to 0.85, respectively. Complete remission was achieved in 3 of 7 cases (48%), and partial remission was achieved for the remaining 4 (52%). Therefore, at least some remission was achieved in all patients in this study. Discussion & Conclusions The central anticholinergic drug trihexyphenidyl is a novel and successful medical therapy in reducing flashbacks in subjects suffering from PTSD. This result suggests that the origin of flashbacks in PTSD is closely related to abnormal excitement of memory-related circuits comprised of the acetylcholine-based basal forebrain, amygdala, and hippocampus.

Authors

Institutions

Publication Details

Journal
The International Journal of Neuropsychopharmacology
Published
2025-08-01
DOI
https://doi.org/10.1093/ijnp/pyaf052.021
Primary Topic
Anesthesia and Neurotoxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

208. TRIHEXYPHENIDYL REDUCES FLASHBACKS IN PATIENTS WITH POSTTRAUMATIC STRESS DISORDER (PTSD)

Katsumasa Sogo
The International Journal of Neuropsychopharmacology
Anesthesia and Neurotoxicity Research
article

208. TRIHEXYPHENIDYL REDUCES FLASHBACKS IN PATIENTS WITH POSTTRAUMATIC STRESS DISORDER (PTSD)

Katsumasa Sogo
article en

Abstract

Abstract Background Post-Traumatic Stress Disorder (PTSD) is a complex mental health condition triggered by experiencing or witnessing traumatic events. Despite extensive research, the precise mechanisms underlying PTSD remain unclear. Recent data from patients have shown that central cholinergic agents targeting the basal forebrain nucleus AcH4 and the amygdala, which are involved in memory-related circuits, have demonstrated dramatic effects in alleviating PTSD symptoms. Aims & Objectives This study aims to develop a new therapy for reducing flashbacks in the posttraumatic stress disorder (PTSD). Method Previous studies have proved the potentiality of anticholinergic in reducing flashbacks in PTSD. This report describes the effects of the central anticholinergic drug trihexyphenidyl, which penetrates the blood–brain barrier (BBB) among 7 patients suffering from PTSD flashbacks. Results Drug effects were assessed using psychological tests, including a self-evaluation score, the IES-R (Impact of Events Scale-Revised), and CAPS (Clinician-administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders-IV [DSMIV]).The mean of the self-evaluation score improved from 100 to 17.14 after the treatment, and the mean IES-R score improved to 25.57 from 70.42. The CAPS mean frequency (F) and intensity (I) of B-1(unwanted memories) improved from 3.42 to0.71and 3.42 to 0.57, respectively, after treatment. The mean F and I of B-2 (unpleasant dreams) improved from 1.85 to 0.42and 2.00 to 0.28, respectively. The mean of F and I of B-3 (flashbacks, etc.) improved from 3.71 to 0.85 and 3.28 to 0.85, respectively. Complete remission was achieved in 3 of 7 cases (48%), and partial remission was achieved for the remaining 4 (52%). Therefore, at least some remission was achieved in all patients in this study. Discussion & Conclusions The central anticholinergic drug trihexyphenidyl is a novel and successful medical therapy in reducing flashbacks in subjects suffering from PTSD. This result suggests that the origin of flashbacks in PTSD is closely related to abnormal excitement of memory-related circuits comprised of the acetylcholine-based basal forebrain, amygdala, and hippocampus.

The International Journal of NeuropsychopharmacologyVol. 28(Supplement_2)
Southern Leyte State University (PH)
Openalex Percentile: Top 76%
Anesthesia and Neurotoxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.